Purpose | How to Apply | MyErice | Contacts | FAQ

Click here to see the scientific program

and here to see a day-by-day program

Eddy Arnold, CABM and Rutgers University, Piscataway NJ, US: Targeting resistance in design of anti-AIDS drugs
Joseph D. Bauman, Rutgers University, Piscataway NJ, US: X-ray crystallographic fragment screening
Helen Berman, RCSB Protein Data Bank and Rutgers University, Piscataway NJ, US: The Protein Data Bank as a resource for drug design
Jeffrey Blaney, Genentech Inc., UCSF CA, US: Molecular Modeling and Drug Design
Tom L.Blundell, Cambridge University, Cambridge, UK: Targeting protein: protein interactions
Chun-wa Chung, GlaxoSmithKline, Stevenage, UK: Drug design targeting bromodomains
Miles Congreve, Heptares Therapeutics Ltd, Welwyn Garden City, UK: Engineering GPCRs for drug design
Steven Cusack, EMBL, Grenoble, FR: Targeting Influenza virus polymerase
Helena Danielson, Uppsala University, Uppsala, SE: Molecular interaction analysis for resolving biological function and discovery of drugs
Colin Groom, CCDC, Cambridge, UK: The small molecule universe
Michael M.Hann, GlaxoSmithKline, Stevenage, UK: Molecular obesity and other addiction in drug discovery
John J.Irwin, Toronto University, Toronto ON, CA: Docking Experiences and expectations
Gerhard Klebe, Philipps University, Marburg, DE: Energetics of protein-ligand interactions
*** Brian K.Kobilka, Stanford University, Palo Alto CA, US: GPCR structures
Andrew Kruse, Stanford University, Palo Alto CA, US: GPCR structures
*** Viktor Lamzin, EMBL, Hamburg, DE: Using ARP/WARP for structure-based drug design
* Alastair D.G.Lawson, UCB, Slough, UK: Antibody technologies to stabilize targets for NCE screening
Richard Pauptit, AstraZeneca, Macclesfield, UK: Drug design tales
Alberto Podjarny, IGBMC, Illkirch, FR: High resolution protein ligand interactions by x-ray and neutron diffraction
** Michael G.Rossmann, Purdue University, West Lafayette IN, US: Virus Structures and antiviral drug design
Giovanna Scapin, Merck & Co, Kenilsworth NJ, US: Structure-based drug design of drugs against diabetes
Oliver Smart, Global Phasing Ltd., Cambridge UK: Achieving high quality protein-ligand X-ray structures for drug design
Robert Stroud, UCSF, San Francisco CA, US: Membrane protein structures
Anna Tramontano, University of Rome “La Sapienza”, Rome, IT: Structural bioinformatics
Salvador Ventura, UAB, Barcelona, ES: Protein Aggregation and Drug Design
James A.Wells, UCSF, San Francisco CA, US: Turning on enzymes with small molecules

* Withdrawn in July 2013 due to personal circumstances
** Withdrawn in January 2014
*** Withdrawn in May 2014 because of health issues